Reproductive medicine and biology · 2026
Total Testosterone Measured by Liquid Chromatograph-Tandem Mass Spectrometry Refines Diagnosis of Biochemical Hyperandrogenism and Better Identifies Subgroup at Genuine Risk of Adverse Fertility Outcomes in Women With Polycystic Ovary Syndrome.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Jian, Wu Qi, Cong Jing, Chang Hui, Ma Hong-Li, Zhang Duo-Jia, Wang Yu, Zhang Rui-Zhe, Kam Richard K T, Ho Chung Shun, Chan Michael Ho Ming, Ma Ronald Ching Wan, Ng Ernest Hung Yu, Mol Ben Willem J, Stener-Victorin Elisabet, Legro Richard S, Wang Chi Chiu, Wu Xiao-Ke, PCOSAct Study Group
Аннотация
PURPOSE: To compare total testosterone (TT) measured by liquid chromatograph-tandem mass spectrometry (LC-MS/MS) with electro-chemiluminescent immunoassay (ECLIA) in the diagnosis and management of infertile women with polycystic ovary syndrome (PCOS).
METHODS: Baseline TT was measured by LC-MS/MS and ECLIA in 906 infertile women with PCOS. The associations of TT from both methods with clinical phenotypes and fertility outcomes were estimated; relative risk (RR) and 95% confidence intervals (CIs) were computed. Subgroup analysis was conducted according to the TT levels.
RESULTS: The average TT levels measured by ECLIA were higher than those measured by LC-MS/MS (mean percentage difference 23.8%, 95% limits of agreement -44.2% to 91.9%). When biochemical hyperandrogenism (HA) defined as TT ≥ 1.7 nmol/L by LC-MS/MS method, a higher proportion of patients were identified having biochemical HA using ECLIA (44.0% vs. 24.0%, p < 0.001) than LC-MS/MS. Only those with TT levels ≥ 1.7 nmol/L measured by LC-MS/MS had an increased risk of adverse fertility outcomes compared to patients with normal TT levels, including ovulation, preterm labor, and neonatal intensive care unit.
CONCLUSION: Our findings indicated that LC-MS/MS refined the diagnosis of biochemical hyperandrogenism and better identified the subgroup at genuine risk of adverse fertility outcomes in infertile women with PCOS.
TRIAL REGISTRATION: The NIH Clinical Trial Registry number: NCT01573858 and Chinese Clinical Trial. Registry number: ChiCTR-TRC-12002081.
METHODS: Baseline TT was measured by LC-MS/MS and ECLIA in 906 infertile women with PCOS. The associations of TT from both methods with clinical phenotypes and fertility outcomes were estimated; relative risk (RR) and 95% confidence intervals (CIs) were computed. Subgroup analysis was conducted according to the TT levels.
RESULTS: The average TT levels measured by ECLIA were higher than those measured by LC-MS/MS (mean percentage difference 23.8%, 95% limits of agreement -44.2% to 91.9%). When biochemical hyperandrogenism (HA) defined as TT ≥ 1.7 nmol/L by LC-MS/MS method, a higher proportion of patients were identified having biochemical HA using ECLIA (44.0% vs. 24.0%, p < 0.001) than LC-MS/MS. Only those with TT levels ≥ 1.7 nmol/L measured by LC-MS/MS had an increased risk of adverse fertility outcomes compared to patients with normal TT levels, including ovulation, preterm labor, and neonatal intensive care unit.
CONCLUSION: Our findings indicated that LC-MS/MS refined the diagnosis of biochemical hyperandrogenism and better identified the subgroup at genuine risk of adverse fertility outcomes in infertile women with PCOS.
TRIAL REGISTRATION: The NIH Clinical Trial Registry number: NCT01573858 and Chinese Clinical Trial. Registry number: ChiCTR-TRC-12002081.